Clinical Trial

The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-04-30; most recent amendment 2025-08-13.
Status change: Recruiting → Active, Not Recruiting 2025-08-13
Status change: Not Yet Recruiting → Recruiting 2022-06-16
Trial Details
NCT Number NCT05360615
Lead Sponsor Chulalongkorn University
Conditions Empagliflozin in Post AKI Stage 2-3
Enrollment 147 participants
Start Date 2022-07-01
Primary Completion 2024-06-01 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-17